FDA panel considers an injectable drug that prevents RSV in infants

An FDA committee will decide whether to recommend a monoclonal antibody drug from AstraZeneca and Sanofi that can protect infants up to 2 years old from RSV.

from NBC News Top Stories https://ift.tt/yJ4oELt